CervoMed's Neflamapimod Granted UK Innovation Passport for Dementia with Lewy Bodies

CervoMed Inc. announced that its lead drug candidate, neflamapimod, has been awarded an Innovation Passport designation in the United Kingdom. This designation provides entry into the Innovative Licensing and Access Pathway (ILAP) for its development as a treatment for Dementia with Lewy Bodies (DLB), a program designed to accelerate time to market for innovative medicines.

Key Details

• Drug Candidate: Neflamapimod, an oral, small molecule drug candidate for age-related brain disorders.
• Designation: Granted an Innovation Passport to enter the UK's Innovative Licensing and Access Pathway (ILAP).
• Indication: For the treatment of Dementia with Lewy Bodies (DLB), a condition with high unmet need and no currently approved treatments in the U.S. or E.U.
• Pathway Benefits: The ILAP aims to expedite patient access by providing early, coordinated guidance from the UK's MHRA (regulatory), NHS (health system), and HTA (health technology assessment) bodies.